MicroPort NeuroTech Limited (HKG: 2172), a Chinese medical device company, has announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its product NUMEN Silk, a spring coil embolization system that marks its first international approval. This milestone follows the initial approval of the NUMEN system in China in September 2020 and subsequent approvals in the European Union, the United States, South Korea, Brazil, and Japan.
NUMEN Silk is an enhanced version of the NUMEN spring coil embolization system, designed for the embolization treatment of small, medium-sized, and ruptured aneurysms. The product features a three-dimensional “Ω+S” structure that conforms to the irregular walls of tumors, offering a range of diameter and length specifications to meet the needs of various clinical scenarios.
The FDA approval of NUMEN Silk is a testament to MicroPort NeuroTech’s commitment to innovation and quality, providing neurosurgeons with a versatile tool for the treatment of aneurysms and enhancing patient care.- Flcube.com
